

# The Scientific Misconduct Story Behind Ivermectin

By [Dr. Joseph Mercola](#)

Global Research, January 26, 2022  
[Mercola](#)

Region: [USA](#)

Theme: [Media Disinformation](#), [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@globalresearch\\_crg](#).

\*\*\*

*In mid-February 2021, Dr. Andrew Hill at Liverpool University published a scientific meta-analysis of six randomized controlled trials involving the use of ivermectin. The review, funded by the World Health Organization and UNITAID, found the drug increased viral clearance and reduced COVID-19 deaths by 75%, yet the conclusion of the paper was dismissive*

*In early April 2021, Hill was accused of scientific misconduct by the French civic group, Association BonSens. BonSens claims Hill manipulated data to downplay the usefulness of ivermectin. Hill admitted that the study sponsor had crafted the conclusion*

*In early August 2021, Hill published a public notice stating one of the six studies included in his analysis had been withdrawn due to fraudulent data. A revised analysis excluding that study was published in November 2021*

*In the November revision, Hill included 23 randomized clinical trials, concluding ivermectin had no statistically significant effect on survival or hospitalizations*

*Other meta-analyses of 13 to 24 studies have found reductions in death ranging from 62% to 91%. Recent research has also found a five-day course of ivermectin at a dose of 12 mg per day sped up viral clearance, reducing the duration of symptomatic illness by three days compared to placebo (9.7 days versus 12.7 days)*

\*

In mid-February 2021, **Dr. Andrew Hill** at Liverpool University published a scientific meta-analysis of six randomized controlled trials involving the use of ivermectin in 1,255 COVID-19 patients. (The paper was initially posted on a preprint server.)

The review, which was funded by the World Health Organization and UNITAID, found that ivermectin increased viral clearance and reduced COVID-19 deaths by 75%. This is a rather massive benefit, yet the conclusion of the paper was dismissive, saying additional large

clinical trials were needed to make a determination about whether or not to recommend its use.

### **Hill Accused of Scientific Misconduct**

In early April 2021, Hill and his coauthors were accused of scientific misconduct by a French civic group called the Association BonSens. The TrialSite News video report from April 5 above reviews the details of this story. BonSens — labeled by some a “controversial group” based on its anti-mask mandate stance — accused Hill of data manipulation to downplay the usefulness of ivermectin.

According to BonSens, Hill’s analysis was then used by the WHO to recommend against ivermectin, even though it appears to have significant benefit. BonSens called on Hill to retract the paper, but Hill remained “resolute and stands behind the study,” TrialSite News said.

At the time, TrialSite News claimed to have been in conversation with “relevant and associated parties,” some of whom have asked to remain anonymous, who say Hill’s study was in fact modified, but that this was done “separate and apart from the investigator,” and that Hill had no say in the matter.

However, since then, one of the six studies Hill included in his analysis has been withdrawn “due to fraudulent data.” In a public notice<sup>1</sup> dated August 9, 2021, Hill and his coauthors addressed the matter, saying they would submit “a revised version excluding this study, and the currently posted paper will be retracted.” A revised and updated meta-analysis was published in November 2021.<sup>2</sup>

The updated review includes data from 23 randomized clinical trials with a total of 3,349 patients. Studies with “high risk of bias” were excluded. In this analysis, Hill found that “Ivermectin did not show a statistically significant effect on survival or hospitalizations,” and had only “borderline significant effect on duration of hospitalization in comparison with standard of care.”

No significant effect on clinical recovery time was detected. In conclusion, the paper states that the WHO “recommends the use of ivermectin only inside clinical trials.” Curiously, it also states that “a network of large clinical trials is in progress to validate the results seen to date.” What results might those be? Surely, they must be referring to positive results, or else a network of clinical trials would hardly be justified.

### **Positive Ivermectin Studies Largely Barred From Publication**

December 3, 2021, TrialSite News interviewed Dr. Tess Laurie (above) about her own ivermectin analyses and that of Hill. She points out that she was concerned when she saw the initial meta-analysis Hill published, as the conclusion didn’t match the data. The reduction in death was significant, yet the conclusion was dismissive.

Laurie contacted Hill, asking him to explain his conclusion to her. He then told her that the conclusion of the paper was not his own. It had been written by his sponsor — the WHO. Laurie was shocked, she said, as this struck her as a clear conflict of interest.

In the interview, Laurie also discusses the general difficulty researchers have had, since the beginning, in getting papers published that support ivermectin. She admits her own team has downplayed the benefits by using extremely conservative analyses in an effort to get published.

“It seems, if you tell it like it is, you are not going to get published because you might be accused of overstating your case. And if you understate it, you’re told there’s not enough evidence,” Laurie says.

### **Strong Evidence for Ivermectin**

According to Laurie, the evidence for ivermectin in the treatment of COVID-19 is strong. In a previous interview, she reviewed a 13-study meta-analysis that found a 68% reduction in deaths. A follow-up review that included 15 studies found a 62% to 72% reduction in deaths.<sup>3</sup>

A five-day course of ivermectin at a dose of 12 mg per day sped up viral clearance, reducing the duration of symptomatic illness by three days compared to placebo (9.7 days versus 12.7 days).

A meta-analysis<sup>4</sup> by Laurie and her team published in the July-August 2021 issue of the American Journal of Therapeutics, which included 24 randomized controlled trials with a total of 3,406 participants, reported reductions in death ranging between 79% and 91%.

A study published February 2021 also reported that a five-day course of ivermectin at a dose of 12 mg per day sped up viral clearance, reducing the duration of symptomatic illness by three days compared to placebo (9.7 days versus 12.7 days).<sup>5</sup>

According to Laurie, what makes ivermectin particularly useful in COVID-19 is that it works both in the initial viral phase of the illness, when antivirals are required, and in the later inflammatory stage, when the viral load drops off and anti-inflammatories become necessary.

Dr. Surya Kant, a medical doctor in India who has written a white paper<sup>6</sup> on ivermectin, claims the drug reduces replication of the SARS-CoV-2 virus by several thousand times.<sup>7</sup> Kant’s paper led several Indian provinces to start using ivermectin, both as a prophylactic and as treatment for COVID-19 in the summer of 2020.<sup>8</sup>

### **Africa and Japan Defy the Odds With Ivermectin**

Japan and Africa have also defied the odds with ivermectin. As reported by NewsRescue at the end of August 2021, “Melinda Gates, co-chair of the Bill and Melinda Gates foundation predicted disaster in the developing world, but so far she has been dead wrong, at least as far as Africa is concerned.”<sup>9</sup>

Indeed, despite having nearly 1.4 billion people, Africa has maintained one of the lowest COVID caseloads and death rates in the world, accounting for just 4% of the global reported death rate as of mid-May 2021.<sup>10</sup> While media feign confusion, ivermectin may well be the

explanation for this phenomenon.

A study<sup>11</sup> published at the end of December 2020 found that African countries that participated in the African Program for Onchocerciasis Control (APOC), where intensive ivermectin mass campaigns were carried out between 1995 and 2015, had 28% lower COVID-19 mortality and 8% lower infection rates than non-APOC countries that did not participate in the ivermectin campaign.

“That a mass public health preventive campaign against COVID-19 may have taken place, inadvertently, in some African countries with massive community ivermectin use is an attractive hypothesis,” the authors said.<sup>12</sup>

Similarly, Japan has seen a massive decline in cases after adopting ivermectin as standard treatment against COVID. November 3, 2021, Free West Media reported:<sup>13</sup>

“The head of the Tokyo Medical Association appeared on national television in September urging doctors to use Ivermectin and they listened. A little over a month later, COVID-19 is under control in Japan ...

Japan had slavishly adhered to all the Big Pharma prescriptions, including quarantine, contact tracing, masking, social distance, but finally the pandemic had hit them hard after they started aggressive vaccination in May 2021.

The results looked good initially, but in mid-July they started rising again and on August 6 cases hit a new all-time high and continued to rise.

Ivermectin was allowed as a treatment on August 13 and after 2 weeks the cases started to come down. In fact, they are now down 99% from the peak ... In Japan, doctors can now prescribe it without restrictions, and people can buy it legally from India.”

### **Doctors Urge Acceptance of Ivermectin to Save Lives**

In the U.S., the Frontline COVID-19 Critical Care Alliance (FLCCC) has been calling for widespread adoption of ivermectin, both as a prophylactic and for the treatment of all phases of COVID-19.<sup>14,15</sup>

FLCCC president Dr. Pierre Kory, former professor of medicine at St. Luke’s Aurora Medical Center in Milwaukee, Wisconsin, has testified to the benefits of ivermectin before a number of COVID-19 panels, including the Senate Committee on Homeland Security and Governmental Affairs in December 2020,<sup>16</sup> and the National Institutes of Health COVID-19 Treatment Guidelines Panel January 6, 2021.<sup>17</sup> As noted by the FLCCC:<sup>18</sup>

“The data shows the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover.

Dr. Kory testified that Ivermectin is effectively a ‘miracle drug’ against COVID-19 and called upon the government’s medical authorities ... to urgently review the latest data and then issue guidelines for physicians, nurse-practitioners, and physician assistants to

prescribe Ivermectin for COVID-19<sup>19</sup> ...

... numerous clinical studies — including peer-reviewed randomized controlled trials — showed large magnitude benefits of Ivermectin in prophylaxis, early treatment and also in late-stage disease. Taken together ... dozens of clinical trials that have now emerged from around the world are substantial enough to reliably assess clinical efficacy.”<sup>20</sup>

A one-page summary<sup>21</sup> of the clinical trial evidence for Ivermectin can be downloaded from the FLCCC website. A more comprehensive, 31-page review<sup>22</sup> of trials data has been published in the journal *Frontiers of Pharmacology*.

At the time of this writing, the number of trials involving ivermectin has risen to 71, including 31 randomized controlled trials. A listing of all the ivermectin trials done to date, with links to the published studies, can be found on [c19Ivermectin.com](http://c19Ivermectin.com).<sup>23</sup>

The FLCCC’s COVID-19 protocol was initially dubbed MATH+ (an acronym based on the key components of the treatment), but after several tweaks and updates, the prophylaxis and early outpatient treatment protocol is now known as I-MASK+<sup>24</sup> while the hospital treatment has been renamed I-MATH+,<sup>25</sup> due to the addition of ivermectin.

The two protocols<sup>26,27</sup> are available for download on the FLCCC Alliance website in multiple languages.

### **Take Control of Your Health Care**

If COVID-19 were an actual medical crisis and not an excuse for a tyrannical power grab, doctors would have been allowed, indeed encouraged, to work together to find solutions. Their successes would then have been announced everywhere. Without doubt, ivermectin would have featured heavily in such reports, as doctors around the world have attested to its benefits.

That’s not what happened, though, which tells us we’re not dealing with a medical crisis that governments actually want to solve. As reported by the FLCCC, its members have “been blocked in attempts to disseminate scientific information about ivermectin on Facebook and other social media with the FLCCC’s pages repeatedly being shut down.”<sup>28</sup>

Seasoned researchers like Laurie can’t get their research published, and the main thing they have in common is that they’re reporting positive results using ivermectin (and other common remedies). For nearly two years now, doctors and scientist have repeatedly shown we can control the COVID endemic, even with new variants. We can save the vast majority from severe illness and death.

Yet “authorities” within government, regulatory agencies and health agencies have refused to listen and insist there’s only one way forward — we need novel gene transfer injections that direct our cells to churn out the very toxin that makes COVID-19 so problematic. And when those shots are proven failures, the answer, these same “leaders” say, is more boosters!

Insanity is doing the same thing over and over, expecting different results. The good news is you can choose who you listen to. You can listen to frontline medical experts, like the FLCCC, and follow their advice.

\*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg\_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

## Notes

<sup>1</sup> [Open Forum Infectious Diseases August 9, 2021; 8\(8\): ofab394](#)

<sup>2</sup> [Open Forum Infectious Diseases November 2021; 8\(11\): ofab358](#)

<sup>3</sup> [YouTube Ivermectin Discussion with Dr. Tess Laurie April 7, 2021](#)

<sup>4</sup> [American Journal of Therapeutics July/August 2021; 28\(4\): e434-e460](#)

<sup>5</sup> [International Journal of Infectious Diseases February 2021; 103: 214-216](#)

<sup>6</sup> [Indian Journal of Tuberculosis July 2020; 67\(3\): 448-451](#)

<sup>7</sup> [Antiviral Research June 2020; 178: 104787](#)

<sup>8</sup> [Financial Express April 14, 2021](#)

<sup>9, 10</sup> [NewsRescue August 31, 2021](#)

<sup>11, 12</sup> [Colomb Med \(Cali\) December 30, 2020; 51\(4\): e2014613](#)

<sup>13</sup> [Free West Media November 3, 2021](#)

<sup>14, 16, 19</sup> [FLCCC December 8, 2020](#)

<sup>15</sup> [Medpage Today January 6, 2021](#)

<sup>17</sup> [FLCCC January 7, 2021 Press Release \(PDF\)](#)

<sup>18, 28</sup> [Newswise December 8, 2020](#)

<sup>20</sup> [FLCCC January 7, 2020 Press Release \(PDF\)](#)

<sup>21</sup> [FLCCC Summary of Clinical Trials Evidence for Ivermectin in COVID-19 \(PDF\)](#)

<sup>22</sup> [Frontiers of Pharmacology 2020 DOI: 10.3389/fphar.2021.643369](#)

<sup>23</sup> [c19ivermectin.com](https://c19ivermectin.com)

<sup>24, 26</sup> [FLCCC Alliance I-MASK+ Protocol](#)

<sup>25, 27</sup> [FLCCC MATH+ Hospital Protocol](#)

*Featured image is from Zero Hedge*

The original source of this article is [Mercola](#)  
Copyright © [Dr. Joseph Mercola](#), [Mercola](#), 2022

---

**[Comment on Global Research Articles on our Facebook page](#)**

**[Become a Member of Global Research](#)**

Articles by: **[Dr. Joseph Mercola](#)**

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)

[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)